PhagoMed Biopharma GmbH

PhagoMed Biopharma GmbH is an Austrian biotechnology company focused on developing innovative phage-based therapies to combat serious bacterial infections and provide advanced treatment solutions. Founded in 2017 in Austria, PhagoMed Biopharma GmbH specializes in phage therapy for bacterial infections. The company has completed a total of 5 funding deals, with the most recent being a Series A round amounting to EUR 1. 50 mn in November 2021.

The company was acquired by BioNTech SE from Wieland Capital, with financial terms undisclosed. PhagoMed Biopharma GmbH specializes in phage therapy solutions designed to treat antibiotic-resistant bacterial infections. Their offerings include products that harness bacteriophages, which are viruses that specifically target and kill bacteria. These solutions are tailored to integrate into clinical settings, providing healthcare professionals with advanced options for managing resistant infections.

The company’s products are utilized primarily in healthcare environments across Europe, where they address critical healthcare challenges related to antibiotic resistance. The revenue model of PhagoMed Biopharma GmbH is projected to be based on direct sales and partnerships with healthcare providers. The company is focused on creating sustainable revenue streams as it advances its product offerings in the phage therapy market. Looking ahead, PhagoMed Biopharma GmbH plans to expand its product line with new phage-based therapies aimed at specific bacterial infections targeted for launch in the next 12-24 months.

The company is also exploring market expansion opportunities in North America by 2023, leveraging recent funding to support its research and development initiatives. The EUR 1. 50 mn from the Series A round will be utilized to accelerate product development and market entry strategies, enhancing their capacity to meet the growing demand for innovative antibacterial therapies.